EUCLISES CO-FOUNDER NAMED 2015 POWER MEDICINE MAKER
St. Louis, MO – May 19, 2015 – Euclises Pharmaceuticals, Inc., is pleased to announce the selection of the company’s chief scientific officer, John Talley, Ph.D., for The Medicine Maker’s 2015 Power List. A co-founder of Euclises, Dr. Talley invented the company’s EuclicoxibTM platform of third-generation COX-2 inhibitors currently under development in oncology and other indications.
The UK-based magazine’s Power List honors the world’s 100 most influential people in drug discovery and development, from scientists and entrepreneurs to corporate executives and philanthropists. Those included on the list were selected from open nominations and rank-ordered by a jury of experts. In the inaugural 2015 index, released on May 5, Dr. Talley ranks #11 based on his impressive record of drug discovery.
“Dr. Talley is an inventor on more than 200 issued U.S. drug patents and has been instrumental in the discovery of a number of drugs that have achieved market approval, including blockbusters Celebrex® and Prezista®,” said Robert Beardsley, Ph.D., a member of the Euclises Board of Directors. “Clearly, this honor is well-deserved.”
Dr. Talley also previously received the prestigious PhRMA Discoverers Award for his work on Celebrex®. Products that he has invented or played a critical role in developing have targeted HIV, pain and inflammation, cancer, and other diseases, and have collectively generated more than $40 billion in revenue.
“Those of us who are privileged to be colleagues of Dr. Talley have long known that we work alongside an exceptionally talented individual,” said Euclises President & CEO Bobby W. Sandage, Jr., Ph.D. “Formal recognition of his accomplishments is gratifying and reflects the strength of the world-class team that we have assembled in support of our EuclicoxibTM development programs.”
For his part, Dr. Talley highlighted the motivating influence of those who have benefited from these drugs. “It is an honor to be recognized by The Medicine Maker,” he said, “but greater satisfaction lies in knowing that I have made a difference for patients around the globe. Here at Euclises, this inspiration continues to feed my drive to innovate and to advance the frontiers of medical science.”
Euclises Pharmaceuticals, Inc. (Euclises) is a drug discovery and development company focused on novel third-generation cyclooxygenase-2 (COX-2) inhibitors for use in the oncology setting. The company is developing a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary EuclicoxibTM platform. In 2014, Euclises and Guangzhou Institutes of Biomedicine and Health (GIBH) announced a development agreement, under which GIBH is advancing one of the candidates for pain and inflammation indications in China and the two are coordinating mutual development activities. The company is currently headquartered within the BioGenerator Labs at CORTEX and supported by funding from Cultivation Capital, BioGenerator, Missouri Technology Corporation, the St. Louis Arch Angels, and other investors. For more information, visit the Euclises website at www.euclises.com.
Media Relations Contact:
Euclises Pharmaceuticals, Inc.
(314) 932-4032 x317